Drug administration in patients with diabetes mellitus

Drug Safety

Volumn 18, Issue 6, 1998, Pages 441-455

  Gilbert, Richard E ^a,c   Cooper, Mark E ^a   Krum, Henry ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIVER ENZYME; METFORMIN; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ABDOMINAL PAIN; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CATARACT; DIABETES MELLITUS; DIARRHEA; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG USE; FLATULENCE; GALLSTONE; HEMOLYTIC ANEMIA; HUMAN; HYPOGLYCEMIA; JAUNDICE; KIDNEY ARTERY STENOSIS; KIDNEY DISEASE; LACTIC ACIDOSIS; LEUKOPENIA; LIVER FAILURE; LIVER FUNCTION TEST; LIVER METABOLISM; MAJOR CLINICAL STUDY; METABOLIC REGULATION; METABOLISM; NAUSEA; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

ACARBOSE; ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CHROMANS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; SULFONYLUREA COMPOUNDS; THIAZOLES; THIAZOLIDINEDIONES; TRISACCHARIDES;

EID: 0031864010     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199818060-00005     Document Type: Review

References (96)

1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiology 1974; 34: 29-34
2. Wändell PE, Brorsson B, Aberg H. Drug use in patients with diabetes. Diabetes Care 1996; 19: 992-4
3. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokineties and pharmacodynamics in humans. Clin Pharmacokinet 1991; 20: 477-90
4. Adithan C, Sriram G, Swaminathan RP, et al. Differential effect of type I and type II diabetes mellitus on serum ampicillin levels. Int J Clin Pharmacol Ther Toxicol 1989; 27: 493-8
5. Della-Colletta AA, Eller MG. The bioavailability of tolazamide in diabetic patients and healthy subjects [abstract]. Pharm Res 1988; 5: 1301
6. Ishii M, Nakamura T, Kasai F, et al. Altered postprandial insulin requirement in IDDM with gastroparesis. Diabetes Care 1993; 17: 901-3
7. Ruiz-Cabello F, Erill S. Abnormal serum prolein hinding of acidic drugs in diabetes mellitus. Clin Pharmacol Ther 1984; 36: 691-5
8. Gatti G, Crema F, Attardo-Parrinello G, et al. Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus. Ther Drug Monit 1987; 9: 389-91
9. Allen TJ, Cooper ME, O'Brien RC, et al. Glomerular filtration rate in the streptozocin diabetic rat: the role of exchangeable sodium, vasoactive hormones and insulin therapy. Diabetes 1990; 38: 1182-90
10. O'Hare JA, Ferri JB, Brady D, et al. Exchangeable sodium and renin in hypertensive diabetic patients with and without nephropathy. Hypertension 1985; 7 Suppl. II: 43-8
11. Zysset T, Wietholtz H. Differential effect of type I and type II diabetes on antipyrine disposition in man. Eur J Clin Pharmacol 1988; 34: 369-75
12. Adithan C, Sriram G, Swaminathan RP, et al. Effect of type II diabetes mellitus on theophylline elimination. Int J Clin Pharmacol Ther Toxicol 1989; 27: 258-60
13. Salmela PI, Sotaniemi EA, Pelkonen RO. The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus. Diabetes 1980; 29: 788-94
14. Dajani RM, Kayyali S, Saheb SE, et al. A study of the physiological disposition of acetophenetidin by the diabetic man. Comp Gen Pharmacol 1974; 5: 1-9
15. Korrapati MR, Vesta IRE, Cho-Ming L. Theophylline metabolism in healthy nonsmokers and in patients with insulin-dependenl diabetes mellitus. Clin Pharmacol Ther 1995; 57: 413-8
16. Christiansen JS, Gammelgaard J, Frandsen M, et al. Increased kidney size, glomerular filtration rate and renal plasma flow in short-term insulin-dependent diabetes. Diabetologia 1981; 20: 451-6
17. Madacsy L, Bokor M, Kozocsa G. Carbenicillin half-life in children with early diabetes mellilus. Int J Clin Pharmacol Biopharm 1976; 14: 155-8
18. Garcia G, de Vidal EL, Trujilio H. Serum levels and urinary concentrations of kanamycin, bekanamycin and amikacin (BB-KS) in diabetic children and a control group. J Int Med Res 1977; 5: 322-9
19. Baba T, Tomiyama T, Murabayashi S, et al. Enalapril pharmacokinetics in diabetic patients. Lancet 1989; 1: 226-7
20. Berlin I, Grimaldi A, Bosquet F, et al. Decreased beta-adrenergic sensitivity in insulin-dependent diabetic subjects. J Clin Endocrinol Metab 1986; 63: 262-5
21. Nishio Y, Kashiwagi A, Terada M, et al. The effect of cardiac contractile response to epinephrine infusion in subjects with diabetes mellitus. In: Shigeta Y, editor. Best approach to the ideal therapy of diabetes mellitus. Amsterdam: Elsevier Science, 1987: 459-62
22. Packer M, Lee WH, Medina N, et al. Influence of diabetes mellitus on changes in left ventricular performance and renal function produced by converting enzyme inhibition in patients with severe chronic heart failure. Am J Med 1987; 82: 1119-26
23. Sugiyama H, Nakajo Y, Miyano T, et al. Cardiovascular reactivity and plasma renin responses to isoproterenol in diabetics with autonomic neuropathy. In: Sakamato Y, editor. Current topics in clinical and experimental aspects of diabetes mellitus. Amsterdam: Elsevier Science, 1985: 323-7
24. Oates NS, Shah RR, Idle JR, et al. Influence of oxidation polymorphism on phenformin pharmacokinetics and dynamics. Clin Pharmacol Ther 1984; 34: 827-34
25. Bailey CJ, Turner RC. Drug therapy: metformin. New Engl J Med 1996; 334: 574-9
26. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72
27. Bailey CJ, Nattrass M. Treatment-melformin. Ballieres Clin Endocrinol Metab 1988; 2: 455-76
28. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997; 20: 925-8
29. Campbell IW. Metformin and glibenclamide: comparative risks. BMJ 1984; 289: 289
30. Gerich JE. Drug therapy: oral hypoglycemic agents. New Engl J Med 1989; 321: 1231-45
31. Smits P, Bijlstra PJ, Russel FGM, et al. Cardiovascular effects of sulphonylurea derivatives. Diabetes Res Clin Prac 1996; 31 Suppl.: S55-9
32. Lebovitz HE, Melander A. Sulphonylureas: basic aspects and clinical uses. In: Alberti KGMM, DeFronzo RA, Keen H, et al., editors. International textbook of diabetes mellitus. Chichester: John Wiley and Sons, 1992: 745-72
33. Seltzer HS. Drug-induce hypoglycemia: a review based on 473 cases. Diabetes 1972; 21: 955-66
34. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737-54
35. Berger W, Caduff F, Pasquel M, et al. Die relative Häufigkeit der schweren Sulfonylharnstoff-Hypoglykämie in den letzten 25 Jahren in der Schweiz. Schweiz Med Wochenschr 1986; 116: 145-51
36. Groop L, Luzi L, Melander A, et al. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 1987; 36: 1320-8
37. Lehto P, Laine K, Kivisto KT, et al. The effect of pH on the in vitro dissolution of three second generation sulphonylurea preparations - mechanisms of antacid-sulphonylurea interactions. J Physiol Pharmacol 1996; 48: 899-901
38. Quinn DI, Day RO. Guide to clinically important drug interactions. In: Speight TM, Holford NHG, editors. Avery's drug treatment. 4th edition. Auckland: Adis International Ltd, 1997: 1665-1699
39. Spencer CM, Markham A, Troglitazone. Drugs 1997; 54: 89-101
40. Iwamoto Y, Kosaka K, Kuzuya T, et al. Effects of troglitazone. Diabetes Care 1996; 19: 151-6
41. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 916-7
42. Prescribing information for Rezulin. Morris Plains (NJ). Parke-Davies, 1997 Dec
43. Campbell LK, White JR, Campbell RK. Acarbose: its role in the treatment of diabetes mellitus. Ann Pharmacother 1996; 30: 1255-61
44. Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46: 1025-54
45. Fox C, Cull CA, Holman RR. Three year response to randomly allocated therapy with diet, sulphonylurea or insulin in 1592 type 2 diabetic patients [abstract]. Diabet Med 1992; 8 Suppl. 1: 8A
46. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329: 977-86
47. Garg SK, Carmain JA, Braddy KC, et al. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabet Med 1996; 13: 47-52
48. Anderson JHJ, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 1997; 46: 265-7
49. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403-18
50. Krolewski AS, Warram JH, Rand LI, et al. Epidemiologic approach to the etiology of type I diabetes niellilus and its complications. New Engl J Med 1987; 317: 1390-8
51. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
52. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol 1996; 77: 1017-20
53. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-81
54. The Euclid Study Group. The effect of lisinopril on retinopathy in people with insulin dependent diabetes mellitus (IDDM). Diabetologia 1997; 40 Suppl. I: A500
55. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-73
56. DeFronzo RA. Hyperkalaemia and hyporeninaemic hypoaldosteronism. Kidney Int 1980; 17: 118-34
57. Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenoses or renal artery stenosis in solitary kidney. N Engl J Med 1983; 308: 373-6
58. Sawicki PT, Kaiser S, Heinemann L, et al. Prevalence of renal artery stenosis in diabetes mellitus - an autopsy study. J Intern Med 1991; 229: 489-92
59. Ritchie CM, McGrath E, Hadden DR, et al. Renal artery stenosis in hypertensive diabetic patients. Diabet Med 1988; 5: 265-7
60. Cooper ME, Williams B: Addendum regarding renovascular hypertension and renal artery stenosis. In: Mogensen CE, editor. The kidney and hypertension in diabetes mellitus. Boston: Kluwer Academic. In press
61. Schoen RE, Frishman WH, Shamoon H. Hormonal and metabolic effects of calcium channel antagonists in man. Am J Med 1988; 84: 492-504
62. McNally PG, Cooper ME. Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria. In: Mogensen C, editor. The kidney and hypertension in diabetes mellitus. Boston: Kluwer Academic, 1997: 385-96
63. Psaty BM, Heckbert SR, Kocpsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620-5
64. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 546-52
65. Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1999; 21: 597-603
66. Lewis RV, Lofthouse C. Adverse reactions with β-adrenoceptor blocking drugs: an update. Drug Saf 1993; 9: 272-9
67. Kasiske BL, Ma JZ, Kalil RSN, et al. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122: 133-41
68. Williams B. Insulin resistance: the shape of things to come. Lancet 1994; 344: 521-4
69. Feleke E, Lynastrum O, Rastan L, et al. Complaints of cold extremities among patients on antihypertensive treatment. Acta Med Scand 1989; 213: 381-5
70. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of betablocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol 1996; 77: 1273-7
71. Zuanetti G, Maggioni AP, Keane W, et al. Nephrologists neglect administration of betablockers to dialysed diabetic patients. Nephrol Dial Transplant 1997; 12: 2497-500
72. Kjekshus J, Gilpin E, Cali G, et al. Diabetic patients and betablockers after acute myocardial infarction. Eur Heart J 1990; 11: 43-50
73. Bristow MR, Gilbert EM, Abraham WT, et al. Effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischaemic or non-ischaemic dilated cardiomyopathy [abstract]. Circulation 1996; 94: 1-664
74. Harper R, Ennis CN, Heany AP, et al. A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995; 38: 853-9
75. Stevenson JG, Vanstead GS. Sexual dysfunction due to antihypertensive agents. Drug Intell Clin Pharm 1984; 18: 113-21
76. O'Brien AAJ, Bulpitt CJ. Hypertensive disease. In: Speight TM, editor. Avery's drug treatment. 4th edition. Auckland: Adis International, 1997: 897-932
77. Chun BY, Dobson AJ, Heller RF. The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care 1997; 20: 704-8
78. Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary artery bypass surgery with angioplasty in patients with multivessel disease. New Engl J Med 1996; 335: 217-25
79. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intilam hyperplasia: a serial intravascular ultrasound study. Circulation 1997; 95: 1366-9
80. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. New Engl J Med 1995; 333: 1301-7
81. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Sinnasiatin Survival Study (4S). Lancet 1994; 344: 1383-9
82. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996; 335: 1001-9
83. Pyörälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-20
84. Goldberg R, Sacks F, Howard B, et al. Diahetic response to pravastatin during the CARE study [abstract]. Circulation 1996; 94 Suppl. 1: 3159
85. Raskin P, Ganda OP, Schwartz S, et al. Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. Am J Med 1995; 99: 362-9
86. Jokubaitis LA, Knopp RH, Frohlich J. Efficacy and safely of fluvastatin in hyperlipidaemic patients with non-insulin-dependent diabetes mellitus. J Int Med 1994; 236 Suppl. 736: 103-7
87. Bach LA, Wirth A, O'Brien RC, et al. Cholesterol lowering effects of simvastatin in patients with diabetes mellitus. Diabet Nutr Metab 1991; 4: 123-8
88. McNeil JJ, Krum H: Cardiovascular Disorders. In: Speight TM, Holford NHG, editors. Avery's drug treatment. 4th edition. Auckland: Adis International, 1997: 809-96
89. England JD, Walsh JC, Stewart P, et al. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors-simvastatin and pravastatin. Aust N Z J Med 1995; 25: 374-5
90. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 16: 5-13
91. Committee of Principal Investigators. WHO Cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow up. Lancet 1984; 8403: 600-4
92. Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-5
93. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safely of treatment, changes in risk factors, and incidence of coronary heart disease. New Engl J Med 1987; 317: 1237-45
94. Huttunen JK, Heinonen OP, Manninen V, et al. The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Int Med 1994; 235: 41-9
95. Smit JW, Jansen GH, de Bruin TW, et al. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone and in combination does not induce muscle damage. Am J Cardiol 1995; 76: 12A-8
96. Eliav O, Schurr D, Pfister P, et al. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. Am J Cardiol 1995; 76: 76A-9